FDA
-
-
-
-
-
-
-
Proteon Therapeutics (PRTO) Announces Review of Potential Strategic Transactions
-
-
-
-
-
-
-
Proteon Therapeutics (PRTO) Reports Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease
-
-
-
-
-
-
-
Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply
-
-
-
-
-
-
-
Proteon Therapeutics (PRTO) Announces $22M Private Placement of Series A Convertible Preferred Stock
-
-
-
-
-
-
-
Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

